

Press release  
Lund July 8<sup>th</sup> 2021

## Scandinavian ChemoTech starts a feasibility study to evaluate a “Go-to-Market” strategy for Animal Care in the USA

***Today Scandinavian ChemoTech has signed an agreement with the US based company Diversified Consultant Group LLC that will be responsible for performing a feasibility study. This study is aiming at identifying how Scandinavian ChemoTech should design a “Go-to-Market” strategy when launching its animal care product vetIQure in the USA.***

The US market for vetIQure is of great significance as the Cancer therapy market for pets is estimated to over MUSD 800/y and growing with a double-digit rate.

Diversified Consultant Group LLC was founded by the CEO Danny Nesrallah, who has extensive experience from Business development of the older static generation of Electroporation in both the US and Middle East.

*“To investigate our opportunities to enter the US market with our product vetIQure is both thrilling and exciting at the same time. We believe that we really have found the right partner to help us in the initial stages of our North American journey. Danny and his company also ensure that we have leverage from someone with a wide network of existing electroporation users.” - says Mohan Frick, CEO of Scandinavian ChemoTech*

*For more information, please contact:*  
Mohan Frick, CEO

+46 (0)10-218 93 00  
info@chemotech.se

***Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se***

### **Scandinavian ChemoTech AB (publ)**

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: [www.chemotech.se](http://www.chemotech.se)